No spam. Unsubscribe anytime.
Batch purity, right where researchers look for it.
Each included compound carries its own HPLC result, batch reference, and testing date so the research brief is backed by real analytical proof.
Retatrutide
Purity (HPLC)
Tirzepatide
Purity (HPLC)
Semaglutide
Purity (HPLC)
Triple Incretin Comparator Kit
Brings together single-, dual-, and triple-agonist incretin compounds in one comparative kit
A three-compound incretin kit built for researchers who want the full progression from single- to triple-receptor activation.
Research Use Only. These kits are intended for laboratory research purposes only. Not for human consumption. Public-page summaries reflect published literature and analytical documentation, not human-use instructions or treatment claims.
Built from published research, not guesswork.
Every public research kit now leads with the proof: cited studies, PMIDs, tracked signals, and batch-level documentation across each component.
What is inside the kit, structurally
Core chemistry details pulled from each included compound so the page feels like a real research profile, not a generic bundle card.
Retatrutide
CAS: 2381089-83-2Retatrutide is a triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon (GCGR) receptors. GLP-1 and GIP agonism drive insulin secretion and appetite suppression, while glucagon receptor activation increases energy expenditure and hepatic lipid oxidation. This triple mechanism addresses multiple metabolic pathways for potentially superior metabolic research and metabolic improvement over dual agonists.
Tirzepatide
CAS: 2023788-19-2Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously. It stimulates insulin secretion, suppresses glucagon in a glucose-dependent manner, and reduces appetite via central and peripheral signaling. The dual receptor engagement provides synergistic metabolic effects beyond GLP-1 agonism alone, including enhanced lipid metabolism and improved insulin sensitivity.
Semaglutide
CAS: 910463-68-2Semaglutide is a GLP-1 receptor agonist that mimics native GLP-1 to stimulate insulin secretion in a glucose-dependent manner while suppressing glucagon release. The Aib substitution at position 2 confers resistance to DPP-IV enzymatic degradation, and the C18 fatty diacid chain enables high-affinity albumin binding, extending its half-life substantially. It also acts on hypothalamic appetite centers to reduce food intake and delay gastric emptying.
Published study parameters
Typical dose ranges, intervals, and administration routes cited in the literature for the compounds in this kit.
Published protocols reference single-agent or dual-agent use. Sequencing studies typically initiate with Semaglutide for tolerance establishment, then transition to Tirzepatide or Retatrutide. All three require gradual dose escalation over 4-6 weeks per published titration schedules.
Semaglutide
Same day each weekTirzepatide
Same day each weekRetatrutide
Same day each weekThese are publication-style study parameters summarized from cited literature and investigational designs. They are provided as research context only, not as human-use instructions or recommendations.
Why these compounds are paired in the literature
Plain-English summaries of the mechanisms and published pairings that make this kit coherent for real research work.
Semaglutide activates GLP-1 receptors to regulate appetite signaling — the same validated mechanism studied in Ozempic/Wegovy clinical trials (PMID: 33567185).
Tirzepatide engages both GLP-1 and GIP receptors simultaneously. Published SURPASS data shows this dual-agonist approach produces measurably different metabolic outcomes than GLP-1 alone (PMID: 35658024).
Retatrutide is a triple-agonist (GLP-1/GIP/glucagon). Phase 2 trial data published in NEJM showed its tri-receptor mechanism adds a direct lipolysis pathway not present in the other two compounds (PMID: 37351564).
This combination provides research flexibility to study single, dual, and triple-receptor activation independently or in sequence.
What's in This Kit
3 peptides, each with individual COA documentation
Retatrutide
$95.95energy-balance research with extreme metabolic research potential (>24% in trials) · glucose-regulation research management · Triple incretin receptor pharmacology
Retatrutide is a triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon (GCGR) receptors.
Tirzepatide
$224.95glucose-regulation research with superior HbA1c reduction · energy-balance research treatment with significant metabolic research outcomes · Dual incretin receptor pharmacology studies
Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously.
Semaglutide
$86.95glucose-regulation research glucose-regulation research · energy-balance research and metabolic signaling research · cardiometabolic research in diabetic populations
Semaglutide is a GLP-1 receptor agonist that mimics native GLP-1 to stimulate insulin secretion in a glucose-dependent manner while suppressing glucagon release.
Go deeper on the peptides inside the kit
Article picks tied directly to the compounds in this kit, so researchers can move from the bundle view into peptide-specific literature, mechanism, and handling context.
GLP-1 Reconstitution & Dosing
Comprehensive research guide covering mechanism, studies, and practical info for semaglutide reconstitution.
Tirzepatide Clinical Trials: Summary
Comprehensive research guide covering mechanism, studies, and practical info for tirzepatide clinical trials.
GLP-1 Peptide: Titration & Dosing Protocols
Extremely practical. Very high search volume for GLP-1 dosing. Comprehensive research guide covering mechanism of action, published studies, and practical.
The GLP-1 Revolution Overview
Massive mainstream media coverage. Captures trending searches. Comprehensive research guide covering mechanism of action, published studies, and practical.
Semaglutide vs Tirzepatide: A Comparison
Compare semaglutide and tirzepatide, two leading GLP-1 agonists. Examine mechanisms, selectivity, and research.
Complete Guide to GLP-1 Agonists
In-depth overview of GLP-1 agonists. Covers the incretin system, available compounds, mechanisms, and research.
Related Research Kits
Incretin Pathway Comparator Kit
Single vs. dual receptor activation — the compounds from the STEP and SURPASS trials
2 peptides · Metabolic Research
Lipolytic Pathway Study Kit
Three lipolytic mechanisms studied in published research — HGH-fragment activity plus mitochondrial oxidation
3 peptides · Metabolic Research
Tissue Repair Research Kit
The two most-cited tissue repair peptides studied together in published literature
2 peptides · Tissue Research
Start Your Research
Get the complete Triple Incretin Comparator Kit at $346.67 — save $61.18 versus purchasing each compound separately. Full COA documentation included with every vial.
Research Use Only. These kits are intended for laboratory research purposes only. Not for human consumption. Public-page summaries reflect published literature and analytical documentation, not human-use instructions or treatment claims.